Pfizer joins Beam Therapeutics to develop rare disease therapies

Reuters2022-01-10

Jan 10 (Reuters) - Drugmaker Pfizer will collaborate with gene-editing specialist Beam Therapeutics in a deal worth as much as $1.35 billion to develop therapies for rare genetic diseases.Beam will ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Jiaok
2022-01-10
Jiaok
Nice

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2202222459?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-01-10 19:11","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2202222459","market":"us","top_or_hot":-1,"title":"Pfizer joins Beam Therapeutics to develop rare disease therapies","media":"Reuters","content":"<div>\n<p>Jan 10 (Reuters) - Drugmaker Pfizer will collaborate with gene-editing specialist Beam Therapeutics in a deal worth as much as $1.35 billion to develop therapies for rare genetic diseases.Beam will ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizer-joins-beam-therapeutics-develop-110000900.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer joins Beam Therapeutics to develop rare disease therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer joins Beam Therapeutics to develop rare disease therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-10 19:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pfizer-joins-beam-therapeutics-develop-110000900.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Jan 10 (Reuters) - Drugmaker Pfizer will collaborate with gene-editing specialist Beam Therapeutics in a deal worth as much as $1.35 billion to develop therapies for rare genetic diseases.Beam will ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pfizer-joins-beam-therapeutics-develop-110000900.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4550","symbol_name":"红杉资本持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/pfizer-joins-beam-therapeutics-develop-110000900.html","article_id":"2202222459","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2202222459","pubTimestamp":1641813060,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Jan 10 (Reuters) - Drugmaker Pfizer will collaborate with gene-editing specialist Beam Therapeutics ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","BEAM":"Beam Therapeutics, Inc.","PFE":"辉瑞","BK4534":"瑞士信贷持仓"},"translate_title":"辉瑞与Beam Therapeutics合作开发罕见疾病疗法","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":1,"BEAM":0.9},"content_text":"Jan 10 (Reuters) - Drugmaker Pfizer will collaborate with gene-editing specialist Beam Therapeutics in a deal worth as much as $1.35 billion to develop therapies for rare genetic diseases.Beam will receive $300 million in upfront payment and lead research activities till three new therapy targets are selected for development from outside the firm's existing programs, the companies said on Monday.Pfizer will then be responsible for development and regulatory activities for the targets, with the option to opt in on exclusive, worldwide licenses for each.Biotech firm Beam, which went public in February 2020, uses gene-editing technology to develop treatments for rare genetic diseases.Gene therapies aim to correct certain diseases by replacing the missing or mutated version of a gene found in a patient's cells with healthy copies, making them the world's most expensive drugs.Last year, Beam entered a partnership https://bit.ly/3t4vcmO with Apellis Pharmaceuticals for six research programs.If Beam chooses to co-develop and co-commercialise any target under the Pfizer agreement, it will be entitled to 35% of the total net profits and costs.Beam is also eligible to receive royalties on net sales for each target under the agreement that has an initial term of four years and can be extended for an additional year.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9006410280,"gmtCreate":1641816124357,"gmtModify":1676533650124,"author":{"id":"4104666637164270","authorId":"4104666637164270","name":"Jiaok","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4104666637164270","idStr":"4104666637164270"},"htmlText":"Nice","listText":"Nice","text":"Nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006410280","repostId":2202222459,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":32,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2202222459"}